Stock Movers Cidara Therapeutics Surges; Stubhub Tumbles; WBD Rallies
Nov 14, 2025
Bloomberg journalist Lisa Mateo joins to discuss key corporate moves. Cidara Therapeutics saw a huge surge after Merck's $9.2 billion cash acquisition, aimed at bolstering their drug portfolio ahead of significant patent expirations. Stubhub's shares tumbled 20% due to a lack of quarterly guidance, raising eyebrows among investors. Meanwhile, Warner Bros. Discovery is in play, attracting bids from major players like Paramount and Netflix, while ensuring CEO David Zaslav's stock options remain secure.
AI Snips
Chapters
Transcript
Episode notes
Merck’s Big Bet To Replace Keytruda Revenue
- Merck agreed to buy Cidara Therapeutics for $221.50 a share, valuing the deal at about $9.2 billion.
- The acquisition reflects Merck's push to replace roughly $18 billion in sales at risk from upcoming Keytruda patent expirations.
Acquisition Trend To Shore Up Drug Pipeline
- Merck has been pursuing multiple acquisitions this year, including Verona Pharma in July for about $10 billion.
- The company is actively expanding its respiratory and infectious-disease portfolio ahead of major patent cliffs.
Provide Guidance After IPOs To Calm Markets
- Investors penalized StubHub for refusing to give quarterly guidance after its IPO, sending shares down sharply.
- If you run a newly public company, provide at least near-term guidance to avoid investor uncertainty and heavy selling.